Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | PARL | Q9H300 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045568 | 0.91 | PSIP1 (0.44) | PSIP1PARLALDH1A1HSD11B1ATM | |
| SCHEMBL3447252 | 0.90 | PSIP1 (0.45) | PSIP1PARLALDH1A1HSD11B1ATM | |
| SCHEMBL5590961 | 0.88 | PSIP1 (0.43) | PSIP1PARLALDH1A1HSD11B1ATM | |
| SCHEMBL2058282 | 0.83 | PARL (0.46) | PSIP1PARLALDH1A1HSD11B1HTR6 | |
| SCHEMBL3448335 | 0.83 | HSD11B1 (0.42) | PSIP1PARLALDH1A1HSD11B1ATM | |
| SCHEMBL16053872 | 0.83 | HTR6 (0.40) | PSIP1PARLALDH1A1HSD11B1ATM | |
| SCHEMBL476998 | 0.82 | PSIP1 (0.47) | PSIP1PARLALDH1A1HSD11B1ATM | |
| SCHEMBL2057211 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAKMT2ACYP2C19 | |
| SCHEMBL22265083 | 0.82 | PARL (0.39) | PSIP1PARLALDH1A1HSD11B1ATM | |
| SCHEMBL11049643 | 0.82 | PARL (0.44) | PSIP1PARLALDH1A1HSD11B1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9065146-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8551662-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8404802-B2 | a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma | GE HEALTHCARE AS (NO) | 2013-03-26 | — | — | US | disclosed |
| US-8029935-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20110229771-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| US-7981553-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20110159380-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100227226-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100021823-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| US-7575833-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080187493-A1 | a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma | GE HEALTHCARE AS (NO) | 2008-08-07 | — | — | US | disclosed |
| US-7351790-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2008-04-01 | — | — | US | disclosed |
| US-20070238025-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-10-11 | — | — | US | disclosed |
| US-7223502-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| EP-1272507-B1 | INTEGRIN BINDING PEPTIDE DERIVATIVES | AMERSHAM HEALTH AS (NO) | 2005-06-29 | — | — | EP | disclosed |
| US-20050118512-A1 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20030204049-A1 | Peptide-based compounds | GE HEALTHCARE LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204049-A1 | Peptide-based compounds | ITGB3, ITGAV, SELPLG | PSIP1 1461/4885PARL 1738/4885ALDH1A1 4667/4885 |
| US-20080187493-A1 | a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma | KDR, VCAM1, FLT1 | PSIP1 2507/4885PARL 4469/4885ALDH1A1 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.